The evaluation of the longitudinal change in tau burden in patients with Alzheimer's disease (AD) via tau positron emission tomography (PET) is crucial for understanding the pathological progression and potential response to intervention in clinical trials. This evidence concerns the gene MAPT and Alzheimer disease.